D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder, Delusional Disorder

In brief

This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will examine DCS effects on memory consolidation and cognitive flexibility as possible mediators of DCS enhancement of CBT for delusions.

Key facts

Study ID

NCT01981759

Run by

NYU Langone Health

People needed

58

Starts

2014-02-01

Expected to finish

2017-10-01

Last updated by the study team

2020-03-25

Who can join

Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-68
• Diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder
• Treated with any antipsychotic except clozapine for at least 8 weeks or antipsychotic naive for lifetime
• Willing to participate in CBT
• Sufficient proficiency in English to complete assessments
• Score of at least 3 on the SAPS at two assessments, four weeks apart

You may not qualify if…

• Current treatment with clozapine
• SSRI treatment
• Active alcohol or other substance abuse within six weeks
• Unstable medical illness
• Pregnant or nursing
• Anemia
• Renal insufficiency

Where it is running

• Sheppard Pratt — Baltimore, Maryland, United States
• New York Langone Medical Center/Bellevue Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.